I-Mab to Participate at the Truist Securities BioPharma Symposium

Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a US-based global biotech company focused on cancer immunotherapies, has announced its participation in the Truist Securities BioPharma Symposium on November 7, 2024. The company's management team, including Interim CEO Sean Fu, CFO Joe Skelton, CMO Phillip Dennis, and Senior Director of Investor Relations Tyler Ehler, will engage in one-on-one and small group meetings with investors during the event.

News Market Reaction – IMAB

+0.85%

+0.85% Session move

In the trading session that priced this news, IMAB gained 0.85%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024.

Event Details

Meeting Date	Thursday, November 7, 2024
Meetings	One-on-one and small group meetings: November 7, 2024
Management Participants	Sean Fu, PhD, MBA, Interim Chief Executive Officer (CEO) Joe Skelton, Chief Financial Officer (CFO) Phillip Dennis, MD, PhD, Chief Medical Officer (CMO) Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Truist Securities representative.

About I-Mab

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

For more information, please contact:

Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-truist-securities-biopharma-symposium-302287758.html

SOURCE I-Mab Biopharma

FAQ

When is I-Mab (IMAB) participating in the Truist Securities BioPharma Symposium?

I-Mab will participate in the Truist Securities BioPharma Symposium on November 7, 2024.

Which executives from I-Mab (IMAB) will attend the Truist Securities BioPharma Symposium?

The attending executives include Sean Fu (Interim CEO), Joe Skelton (CFO), Phillip Dennis (CMO), and Tyler Ehler (Senior Director, Investor Relations).

What type of meetings will I-Mab (IMAB) conduct at the Truist Securities BioPharma Symposium?

I-Mab will conduct one-on-one and small group meetings with investors at the symposium.

What is I-Mab's (IMAB) primary business focus?

I-Mab is a US-based global biotech company exclusively focused on developing highly differentiated immunotherapies for cancer treatment.